Application of HPLC in Pharmacokinetic Studies of Cardiovascular Drugs:Ezetimibe and Simvastatin Combination (Vytorin)

Abstract

Dyslipidemia is a significant modifiable risk factor for cardiovascular disease, a leading cause of morbidity and mortality worldwide. The fixed-dose combination of ezetimibe and simvastatin (Vytorin) has complementary lipid-lowering effects via reduction of intestinal cholesterol absorption and inhibition of endogenous cholesterol synthesis. Precise characterization of the pharmacokinetic behavior of these drugs and their active metabolites is essential for evaluation of systemic exposure, bioavailability, bioequivalence, drug interactions, safety and therapeutic performance. High performance liquid chromatography (HPLC) and its advanced hyphenated techniques have become important bioanalytical tools for this purpose due to their selectivity, reproducibility and ability to quantify drugs and metabolites in complex biological matrices. This reviews the application of HPLC based approaches in the pharmacokinetic assessment of ezetimibe and simvastatin with special emphasis on plasma sample preparation, chromatographic separation, detection, method development and bioanalytical validation. Special attention is paid to the analytical determination of ezetimibe, ezetimibe-glucuronide, simvastatin and its pharmacologically active metabolite simvastatin acid. Validated analytical methods are employed for concentration–time profiling and estimation of key pharmacokinetic parameters such as Cmax, Tmax, AUC, elimination half-life and clearance are discussed. Issues concerning low circulating concentrations, interference of biological matrices, stability of metabolites and lactone-acid interconversion are also highlighted. Finally, recent advances in UHPLC, LC–MS/MS, advanced sample preparation and automation, and data-driven chromatographic optimization are taken into account. To summarize, the progress in HPLC-based bioanalysis further strengthens the robustness of pharmacokinetic studies and helps in the rational design and clinical evaluation f combination lipid-lowering therapies.